News

Hosted on MSN2m
Sarepta refuses to pull gene therapy despite FDA order
Sarepta Therapeutics is refusing to pull its gene therapy Elevidys (delandistrogene moxeparvovec), despite a request from the ...
Asianet Newsable on MSN31m
Sarepta Pauses Shipments Of DMD Drug Elevidys Amid FDA Label Review, Stock Tumbles After-Hours
H.C. Wainwright slashed its price target to $0, assigning a 'Sell' rating and saying Sarepta has no remaining intrinsic value ...